Investing.com··Leo MillerLilly's Oral GLP-1 Foundayo Proves Weight-Loss Staying Power in Key Trial
Eli Lilly's oral GLP-1 drug Foundayo retained 80% of weight loss in maintenance trials, bolstering its competitive position against Novo Nordisk's Wegovy.
LLYNVOclinical trial resultspharmaceutical competition